SCHEMBL26567794

SCHEMBL26567794

Cc1ccc2sc(C3CC4(CC(NC(=O)C5CCN(C)C(=O)C5)C4)C3)nc2c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EPHX2 P34913 7/20 0.38
▸ FAAH O00519 1/20 0.38
▸ UBE2M P61081 3/20 0.37
▸ DCUN1D1 Q96GG9 3/20 0.37
▸ LMNA P02545 1/20 0.37
▸ KMT2A Q03164 1/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ ALDH1A1 P00352 2/20 0.35
▸ TP53 P04637 2/20 0.35
▸ ALOX12 P18054 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ THRB P10828 1/20 0.35
▸ HDAC3 O15379 1/20 0.35
▸ HDAC1 Q13547 1/20 0.35
▸ HDAC2 Q92769 1/20 0.35
▸ DYRK1A Q13627 1/20 0.35
▸ ROCK2 O75116 1/20 0.35
▸ CYP3A4 P08684 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29700383 0.91 NPC1 (0.40) NPC1RAB9AALDH1A1TP53MAPT
SCHEMBL26185586 0.91 NPC1 (0.40) NPC1RAB9AALDH1A1TP53MAPT
SCHEMBL26567790 0.84 ROCK2 (0.43) LMNAKMT2AALDH1A1MAPTROCK2
SCHEMBL26567751 0.82 DYRK1A (0.38) EPHX2FAAHUBE2MDCUN1D1LMNA
SCHEMBL26567756 0.80 DYRK1A (0.36) UBE2MDCUN1D1LMNAKMT2ANPC1
SCHEMBL26567808 0.76 DYRK1A (0.38) UBE2MDCUN1D1LMNANPC1RAB9A
SCHEMBL29700375 0.75 ROCK2 (0.47) KMT2ANPC1RAB9AALDH1A1ALOX12
SCHEMBL26185564 0.75 ROCK2 (0.47) KMT2ANPC1RAB9AALDH1A1ALOX12
SCHEMBL26567801 0.73 FASN (0.37) UBE2MDCUN1D1LMNAKMT2AALDH1A1
SCHEMBL26567589 0.73 CHRM4 (0.38) UBE2MDCUN1D1LMNATP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230331715-A1 SPIRO[3.3]HEPTANE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION HOFFMANN-LA ROCHE INC. (US) 2023-10-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230331715-A1 SPIRO[3.3]HEPTANE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION HAVCR2, NR1I3, NR1H4 EPHX2 1124/4885FAAH 4308/4885UBE2M 3500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback